[
    [
        {
            "time": "",
            "original_text": "医药行业周报：逐步布局一季报高增长核心资产",
            "features": {
                "keywords": [
                    "医药行业",
                    "一季报",
                    "高增长",
                    "核心资产"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业周报：逐步布局一季报高增长核心资产",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "国盛证券---医药生物行业周报：全民免疫迫在眉睫，新冠疫苗的热点问题怎么看【行业研究】",
            "features": {
                "keywords": [
                    "医药生物",
                    "全民免疫",
                    "新冠疫苗",
                    "热点问题"
                ],
                "sentiment_score": 0.65,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国盛证券---医药生物行业周报：全民免疫迫在眉睫，新冠疫苗的热点问题怎么看【行业研究】",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业半月谈：医药行业估值性价比开始凸显，适时布局高景气赛道和高成长个股",
            "features": {
                "keywords": [
                    "医药生物",
                    "估值性价比",
                    "高景气赛道",
                    "高成长个股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业半月谈：医药行业估值性价比开始凸显，适时布局高景气赛道和高成长个股",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]